- Home
- TMDX vs YSS Comparison
TMDX vs YSS Comparison
Compare TMDX & YSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMDX | YSS |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.2B |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TMDX | YSS |
|---|---|---|
| Price | $129.52 | $24.32 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $144.25 | N/A |
| AVG Volume (30 Days) | 753.2K | ★ 4.2M |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $566,354,000.00 | $357,460,000.00 |
| Revenue This Year | $38.73 | N/A |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | $52.56 | ★ N/A |
| Revenue Growth | ★ 41.20 | 6.48 |
| 52 Week Low | $62.07 | $22.01 |
| 52 Week High | $156.00 | $38.47 |
Technical Indicators
Market Signals| Indicator | TMDX | YSS |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 31.88 |
| Support Level | $127.00 | $22.01 |
| Resistance Level | $140.72 | $28.56 |
| Average True Range (ATR) | 6.68 | 3.63 |
| MACD | -0.70 | -0.24 |
| Stochastic Oscillator | 13.23 | 18.82 |
Price Performance
Historical ComparisonAbout TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.